Company: CORT
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0001628280-25-048841
Chunk: 44

Company: CORCEPT THERAPEUTICS INC
Filing Date: 2025-11-04
Form: 10-Q
Item: Part I, Item 8
Chunk 44
---
 in “Accrued and other liabilities” on our Unaudited Condensed Consolidated Balance Sheet.Equity Awards OutstandingAs of September 30, 2025, we had 25.1 million stock options, 1.6 million RSAs and less than 0.1 million RSUs outstanding. As of December 31, 2024, we had 24.7 million stock options, 1.2 million RSAs and less than 0.1 million RSUs outstanding.Stock-based CompensationThe following table summarizes our stock-based compensation by financial statement classification:Three Months Ended September 30,Nine Months Ended September 30, 2025202420252024 (in thousands)Capitalized stock-based compensation$141 $95 $392 $223 Cost of sales35 24 98 49 Research and development5,839 4,660 17,557 13,018 Selling, general and administrative17,005 11,418 46,077 31,491 Total stock-based compensation$23,020 $16,197 $64,124 $44,781 

15

7. Net Income Per Share

We compute our basic and diluted net income per share in conformity with the two-class method required for companies with participating shares. Under the two-class method, net income is determined by allocating net income between common stock and unvested RSAs. We compute basic net income per share by dividing our net income attributable to common stockholders by the weighted-average number of common shares outstanding during the period. We compute diluted net income per share by dividing our net income attributable to common stockholders by the weighted-average number of common shares outstanding during the period, including potentially dilutive stock options and unvested RSUs, less unvested RSAs. We use the treasury stock method to determine the number of dilutive shares of common stock resulting from stock options and unvested RSUs.The following table shows the computation of net income per share for each period:Three Months Ended September 30,Nine Months Ended September 30, 2025202420252024 (in thousands, except per share amounts)Numerator:  Net income attributable to common stockholders$19,359 $46,690 $74,267 $109,344 Denominator:Weighted-average shares used to compute basic net income per common share103,545 103,371 103,919 103,